XNYS
ARE
Market cap7.00bUSD
Oct 30, Last price
40.20USD
1D
-0.99%
1Q
-21.87%
Jan 2017
-63.83%
Name
Alexandria Real Estate Equities Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Alexandria Real Estate Equities, Inc. (NYSE:ARE), an S&P 500® real estate investment trust, stands as the pioneering and most seasoned entity in the specialized domain of urban office properties. Since its inception in 1994, Alexandria has uniquely focused on the ownership, operation, and development of integrated campuses tailored for the life science, technology, and agtech sectors, strategically positioned within premier innovation ecosystems. By December 31, 2020, the company commanded a market capitalization of $31.9 billion and managed an extensive North American asset portfolio totaling 49.7 million square feet. This substantial base encompasses 31.9 million RSF of operational properties, 3.3 million RSF of premium Class A spaces currently under construction, 7.1 million RSF designated for near-to-mid-term development and refurbishment, and an additional 7.4 million SF earmarked for future projects. Alexandria has cultivated a significant footprint across vital innovation hubs such as Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland, and Research Triangle. Its established expertise lies in crafting superior Class A facilities within these urban campuses, fostering dynamic and collaborative environments. These spaces are instrumental in empowering innovative tenants to successfully attract and retain world-class professionals, thereby stimulating productivity, efficiency, creativity, and overall achievement. Furthermore, Alexandria extends its support to transformative life science, technology, and agtech companies through its dedicated venture capital platform. This distinct business model, coupled with rigorous underwriting practices, ensures a diverse and high-caliber tenant roster, ultimately driving elevated occupancy rates, extended lease durations, robust rental revenues, superior financial returns, and enhanced long-term asset appreciation.
Related entities
Subsidiaries (3)
Alexandria Venture Investments, LLC
Alexandria Equities No. 7, LLC
ARE-MA Region No. 45, LLC
Key people
Hunter Kass
Co-President, Regional Market Director, Greater Boston · since 2026
Executive Chairman of the Board, Founder · since 2021
Lawrence Diamond
Co-Chief Operating Officer, Regional Market Director, Maryland · since 2018
Joseph Hakman
Co-Chief Operating Officer, Chief Strategic Transactions Officer · since 2020
Madeleine Alsbrook
Executive Vice President - Talent Management · since 2022
John Cole
Executive Vice President - Capital Markets/Strategic Operations and Co-Regional Market Director, Seattle · since 2024
Gary Dean
Executive Vice President - Real Estate Legal Affairs · since 2020
Kristina Fukuzaki-Carlson
Executive Vice President - Business Operations · since 2022
Orraparn Lee
Executive Vice President - Accounting · since 2022
Andres Gavinet
Chief Accounting Officer · since 2012
Peter Moglia
Chief Executive Officer, Chief Investment Officer · since 2023
Jackie Clem
General Counsel, Secretary · since 2020
Marc Binda
Chief Financial Officer, Treasurer · since 2023
Lead Independent Director · since 2016
Claire Aldridge
Independent Director · since 2025
James Cain
Independent Director · since 2015
Independent Director · since 2012
Richard Klein
Independent Director · since 2003
Independent Director · since 2023
Michael Woronoff
Independent Director · since 2017
Legal address
C/O CSC-LAWYERS INCORPORATING SERVICE COMPANY
7 ST. PAUL STREET
SUITE 820
BALTIMORE, MD 21202
US
7 ST. PAUL STREET
SUITE 820
BALTIMORE, MD 21202
US
Headquarters
7 ST. PAUL STREET
SUITE 820
BALTIMORE, MD 21202
US
SUITE 820
BALTIMORE, MD 21202
US
Previous name
Health Science Properties, Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||